|
1
|
Sawyers CL: Chronic myeloid leukemia. N
Engl J Med. 340:1330–1340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kantarjian H and Cortes J: Considerations
in the management of patients with Philadelphia chromosome-positive
chronic myeloid leukemia receiving tyrosine kinase inhibitor
therapy. J Clin Oncol. 29:1512–1516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Hare T, Zabriskie MS, Eiring AM and
Deininger MW: Pushing the limits of targeted therapy in chronic
myeloid leukaemia. Nat Rev Cancer. 12:513–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morotti A, Panuzzo C, Fava C and Saglio G:
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid
leukemia. Expert Opin Biol Ther. 14:287–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crews LA and Jamieson CH: Selective
elimination of leukemia stem cells: Hitting a moving target. Cancer
Lett. 338:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raposo G and Stoorvogel W: Extracellular
vesicles: Exosomes, microvesicles, and friends. J Cell Biol.
200:373–383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Pol E, Boing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Liang H, Zhang J, Zen K and Zhang
CY: Secreted microRNAs: A new form of intercellular communication.
Trends Cell Biol. 22:125–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong CS, Muller L, Whiteside TL and
Boyiadzis M: Plasma exosomes as markers of therapeutic response in
patients with acute myeloid leukemia. Front Immunol. 5:1602014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mfonkeu JB Pankoui, Gouado I, Kuaté H
Fotso, Zambou O, Zollo PH Amvam, Grau GE and Combes V: Elevated
cell-specific microparticles are a biological marker for cerebral
dysfunctions in human severe malaria. PLoS One. 5:e134152010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haflidadóttir BS and Ceder Y: Exosomal
microRNAs as potential biomarkers in castration-resistant prostate
cancer. Eur Urol. 67:42–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Belov L, Matic KJ, Hallal S, Best OG,
Mulligan SP and Christopherson RI: Extensive surface protein
profiles of extracellular vesicles from cancer cells may provide
diagnostic signatures from blood samples. J Extracell Vesicles.
5:253552016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moldovan L, Batte K, Wang Y, Wisler J and
Piper M: Analyzing the circulating microRNAs in
exosomes/extracellular vesicles from serum or plasma by qRT-PCR.
Methods Mol Biol. 1024:129–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cantaluppi V, Gatti S, Medica D,
Fiqliolini F, Bruno S, Dereqibus MC, Sordi A, Biancone L, Tetta C
and Camussi G: Microvesicles derived from endothelial progenitor
cells protect the kidney from ischemia-reperfusion injury by
microRNA-dependent reprogramming of resident renal cells. Kidney
Int. 82:412–427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan A, Farber EL, Rapoport AL, Tejada D,
Deniskin R, Akhmedov NB and Farber DB: Transfer of microRNAs by
embryonic stem cell microvesicles. PLoS One. 4:e47222009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun L, Wang HX, Zhu XJ, Wu PH, Chen WQ,
Zou P, Li QB and Chen ZC: Serum deprivation elevates the levels of
microvesicles with different size distributions and selectively
enriched proteins in human myeloma cells in vitro. Acta Pharmacol
Sin. 35:381–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T))method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nievergall E, Ramshaw HS, Yong AS, Biondo
M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL and Hiwase
DK: Monoclonal antibody targeting of IL-3 receptor α with CSL362
effectively depletes CML progenitor and stem cells. Blood.
123:1218–1228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Copland M, Hamilton A, Elrick LJ, Baird
JW, Allan EK, Jordanides N, Barow M, Mountford JC and Holyoake TL:
Dasatinib (BMS-354825) targets an earlier progenitor population
than imatinib in primary CML but does not eliminate the quiescent
fraction. Blood. 107:4532–4539. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou H and Xu R: Leukemia stem cells: The
root of chronic myeloid leukemia. Protein Cell. 6:403–412. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He WA, Calore F, Londhe P, Canella A,
Guttridge DC and Croce CM: Microvesicles containing miRNAs promote
muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci
USA. 111:pp. 4525–4529. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Camussi G, Deregibus MC, Bruno S,
Cantaluppi V and Biancone L: Exosomes/microvesicles as a mechanism
of cell-to-cell communication. Kidney Int. 78:838–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu XJ, Li QB, Zeng C, Zhong Z, You Y and
Zou P: Detection of leukemia-derived microparticles in the
monitoring of chronic myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi.
35:138–141. 2014.(In Chinese). PubMed/NCBI
|
|
24
|
Bouchalova K, Svoboda M, Kharaishvili G,
Vrbkova J, Bouchal J, Trojanec R, Koudelakova V, Radova L, Cwiertka
K, Hajduch M and Kolar Z: BCL2 is an independent predictor of
outcome in basal-like triple-negative breast cancers treated with
adjuvant anthracycline-based chemotherapy. Tumour Biol.
36:4243–4252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gonzalez D, Else M, Wren D, Usai M, Buhl
AM, Parker A, Oscier D, Morgan G and Catovsky D: CLLU1 expression
has prognostic value in chronic lymphocytic leukemia after
first-line therapy in younger patients and in those with mutated
IGHV genes. Haematologica. 98:274–278. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang X, Yuan T, Liang M, Du M, Xia S,
Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal
miR-1290 and miR-375 as prognostic markers in castration-resistant
prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pallasch CP, Patz M, Park YJ, Hagist S,
Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J,
et al: miRNA deregulation by epigenetic silencing disrupts
suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood. 114:3255–3264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaiswal R, Luk F, Gong J, Mathys JM, Grau
GE and Bebawy M: Microparticle conferred microRNA
profiles-implications in the transfer and dominance of cancer
traits. Mol Cancer. 11:372012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG and Sidhu SB: miR-195 and miR-483-5p identified as predictors of
poor prognosis in adrenocortical cancer. Clin Cancer Res.
15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang WZ, Pu QH, Lin XH, Liu MY, Wu LR, Wu
QQ, Chen YH, Liao FF, Zhu JY and Jin XB: Silencing of miR-21
sensitizes CML CD34+ stem/progenitor cells to imatinib-induced
apoptosis by blocking PI3K/AKT pathway. Leuk Res. 39:1117–1124.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naka K, Hoshii T, Muraguchi T, Tadokoro Y,
Kondo Y, Nakao S, Motoyama N and Hirao A: TGF-beta-FOXO signalling
maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Nature. 463:676–680. 2010. View Article : Google Scholar : PubMed/NCBI
|
